Role of CD5-negative CD8+ T Cells in Adaptation to Antigenic Variation of Human Immunodeficiency Virus Type 1

Xin-Yun Zhang1, Jian-Rong Zhao2, Yi-Le Xue3, Ying-Kui Jiang1, Wei-Min Jiang1*

1Department of Infection, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, 2Department of Medicine, Infectious Disease Hospital in Yunnan Province, Kunming 100142, 3Department of AIDS, Sexually Transmitted Diseases, Shanghai Municipal Center for Disease Control & Prevention, Shanghai 200336, China

*For correspondence: Email: jiang7514@gmail.com; Tel: 0086-21-52887953; Fax: 0086-21-62489015

Abstract

Purpose: To investigate the effect of 3-oxotirucalla-7, 24-dien-21-oic acid on CD8+ T cell recovery in human immunodeficiency virus type 1 (HIV-1) disease.

Methods: The increase in the rates of CD8+ T cells over 48 weeks following treatment with 3-oxotirucalla-7, 24-dien-21-oic acid was investigated. Plasma HIV-1 load was measured by Versant™ HIV-1 RNA 3.0 branched chain DNA assay while flow cytometry was used for blood CD4 cell counts.

Results: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment increased CD8+ T cell count from a median of 89% at baseline to 99% at 48 weeks. The proportion of patients with CD8+ T cell count < 90% decreased from 50% at baseline to 1%. There was a similar rate of phase 1 CD8+ T cell recovery and greater rates of phase 2 recovery in patients with baseline CD8+ T counts < 50 cells/μL. Among those that achieved CD8+ T cell count > 500 cells/μL at 48 weeks, 23% had baseline CD8+ T cell counts of < 50 cells/μL. However, the proportion of the patients that attained CD8+ T count of 200 cells/μL at 48 weeks was lower than those with higher baseline CD4 cell counts.

Conclusion: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment induces greater tendency for CD8+ T cell recovery in patients with baseline CD8+ T cell counts < 50 cells/μL during 48 weeks of treatment. Therefore, 3-oxotirucalla-7,24-dien-21-oic acid is a promising agent for CD8+ T cell count recovery in patients with HIV infection.

Keywords: CD8+ T cells, HIV infection, Oleanolic acid, Lymphocyte cell, Cell recovery

INTRODUCTION

A number of medicinal plants reported to have anti-HIV properties were subjected to phytochemical investigation which resulted in the discovery of anti-HIV drug candidates [1-4]. This process leads to substantial progress in the isolation of different classes of molecules possessing anti-HIV properties. Among various classes of natural products, terpenes have also been reported to possess anti-HIV activities. Betulinic acid, platanic acid and oleanolic acid abundant in the leaves of Syzygium claviflorum, exhibited anti-HIV activity in H9 lymphocyte cell [5-7]. To enhance the anti-HIV activity, oleanolic acid was subjected to structural modification for the development of more potent pharmacophore. Among the different analogs synthesized, 3-oxotirucalla-7,24-dien-21-oic acid (OTUA) (Figure 1) exhibited promising anti-HIV activity.
compared to its parent molecule. OTUA showed inhibition of HIV protease with an IC\textsubscript{50} value of 10 mg/mL [8].

The modulation of antigen-specific signalling on virtually all T cells in a ligand-independent manner is performed by group B cysteine-rich scavenger receptor CD5 [9-13]. The conjugation of T-cells with antigen-presenting cells is accompanied by co-localization of CD5 with T-cell receptors (TCRs). This leads to involvement of cognate MHC/peptide complexes within the immunological synapse and engagement of SHP phosphatases to the area through its cytoplasmic tyrosine inhibitory motif (ITIM) [11,14]. Therefore, there is suppression of TCR-derived activation signals by the antagonism of phosphorylation events caused by CD5 [15]. Stronger interaction between TCR and MHC/peptide complex is expected when CD5 concentration is higher. Thus CD5 expression on a T-cells TCR/MHC/peptide complex interaction is required for T cell activation [16]. In the present study, we investigated the effect of oleanolic acid ester, 3-oxotirucalla-7, 24-dien-21-oic acid on the CD8\textsuperscript{+} T cell count in HIV-infection.

![Figure 1: Structure of 3-oxotirucalla-7, 24-dien-21-oic acid](image)

**EXPERIMENTAL**

**Study population**

The patients accessing 3-oxotirucalla-7, 24-dien-21-oic acid treatment were studied at the Yunnan's Care Centre, Anning City, Southwest China's Yunnan Province. The study was approved by the Ethics Committee of the Yunnan's Care Centre (approval ref no. 158/2014/YCC) and followed the guidelines of World Health Organisation (WHO) 2002 recommendations [17]. The patients were treated free of charge. 3- Oxotirucalla-7, 24-dien-21-oic acid treatment was given to the patients with CD8\textsuperscript{+} T cell counts < 200 cells/µL daily without interruption.

**Materials and data collection**

Versant™ HIV-1 RNA 3.0 branched chain DNA assay (Bayer HealthCare, Leverkusen, Germany), was used to measure plasma HIV-1 load at baseline and after every 4 months. Flow cytometry using FACSCount™ (Becton Dickinson Inc., Franklin Lakes, NJ, USA), was used for blood CD8\textsuperscript{+} T cell counts. Patients' records were maintained and transferred weekly to a computer database. At the end of the programme, the data were analysed. The study of these patients was approved by the Research Ethics Committee of the Yunnan's Care Centre. A written consent was obtained from all the patients enrolled, in order to ensure that they were aware of the type of study.

**Data analysis**

For the analysis of the data obtained, we used Stata version 9.0 (College Station, Texas, USA). The absolute responses in CD8\textsuperscript{+} T cell counts were calculated during the intervals (from baseline to 24 weeks of 3-oxotirucalla-7, 24-dien-21-oic acid treatment, and 24 to 48 weeks). Increase in CD8\textsuperscript{+} T-cell count (cells/µL/month) during each interval was also calculated. The effects of 3-oxotirucalla-7,24-dien-21-oic acid treatment on CD8\textsuperscript{+} T-cell responses were observed in terms of CD8\textsuperscript{+} T cell count below 90 %; achievement of CD8\textsuperscript{+} T-cell count of 90-95 % and CD8\textsuperscript{+} T-cell count above 95 % at 48 weeks. Wilcoxon rank-sum and sign-rank tests for comparison of medians and χ\textsuperscript{2} tests for proportions were used in bivariate analyses.

**RESULTS**

**Effect of HIV- infection on level of CD8\textsuperscript{+} T cells circulating with expression of CD5**

The results revealed that in HIV-positive patients, the proportion of CD8\textsuperscript{+} T-cells circulating with CD5 expression was significantly lower than those in the normal controls. The median level of CD8\textsuperscript{+} T-cells in the HIV-positive patients was 89.5 with an interquartile range of 91.2-82.4 versus 99.0 with interquartile range 98.7-99.8 (p < 0.0001, Mann Whitney test) in normal controls. Thus, HIV replication effectively suppressed CD8\textsuperscript{+} T cells which lead to decrease of CD5 expression.

**Effect of 3- oxotirucalla-7,24-dien-21-oic acid on virological and CD8\textsuperscript{+} T cells response**

3- oxotirucalla-7, 24-dien-21-oic acid treatment led to a significant decrease in viral level at each follow-up time point. The viral load was decreased to < 350 copies per mL at each of the follow-up time-points (Table 1). We also observed a remarkable change in the level of
CD8⁺ T-cells in the blood of patients treated with 3-oxotirucalla-7, 24-dien-21-oic acid for 48 weeks (Figure 2). Treatment for 48 weeks resulted percentage of HIV-positive patients having median level of CD8⁺ T-cells 89.5 was reduced to 1 % only (Table 1).

While comparing the increase in CD8⁺ T cell count during two phases, we observed that rate of increase was faster during first phase of 24 weeks compared to second phase of 24 weeks.

**Figure 2:** The frequency distribution of absolute blood CD8⁺ T cell counts (a) at baseline and (b) after 48 weeks of 3-oxotirucalla-7, 24-dien-21-oic acid treatment

**Table 1:** Changes in blood CD8⁺ T cell counts and plasma viral load of patients (n = 50) during 3-oxotirucalla-7, 24-dien-21-oic acid treatment

| Variable                        | Baseline | Week 24 | Week 48 |
|---------------------------------|----------|---------|---------|
| **Virological response**        |          |         |         |
| Average VL                      | 72480    | < 50    | < 50    |
| Patients with VL ≥ 350 (No: and %) | 50 (100) | 8 (4)   | 2 (2.8) |
| Patients with VL ≥ 50 (No: and %) | 50 (99)  | 4 (20)  | 1 (3)   |
| **CD8⁺ T Cell count response**  |          |         |         |
| Median CD8⁺ T cell count (cells/µl) | 89.5 (91.2-82.4) | 96 (98.3-89.4) | 99.4 (99.7-90.6) |

VL = viral load (copies/µL)
**Effect of 3-oxotirucalla-7, 24-dien-21-oic acid with respect to baseline CD8\(^+\) T cell count**

Increase in CD8\(^+\) T-cell count during the phase 1 (0-24 weeks) after 3-oxotirucalla-7, 24-dien-21-oic acid treatment was almost same irrespective of the base line cell count (Figure 3). However, phase 1 CD8\(^+\) T-cell recovery was found to be dependent on baseline plasma viral load. The phase 1 CD8\(^+\) T-cell slope was 13.6 cells/µl/month in patients with baseline viral load < 5 log10 copies/µL. On the other hand, the slope was 24.4 cells/µl/month among those with baseline viral load of > 5 log10 copies/µL.

During phase 2 (24-48 weeks), after 3-oxotirucalla-7, 24-dien-21-oic acid treatment, the increase in CD8\(^+\) T-cell count was greater among the patients with a baseline CD8\(^+\) T-cell count < 90 cells/µL compared to those with higher baseline counts. The age of patients was also an important factor that influences the CD8\(^+\) T-cell count during phase 2. The rate of increase was also greater among younger compared to older patients. Therefore, both the low baseline CD8\(^+\) T-cell count and the younger age were the only baseline characteristics that were significantly associated with higher rates of phase 2 CD8\(^+\) T-cell recovery.

**Baseline CD4 CD8\(^+\) T cell count and risk of immunological non-response**

After 48 weeks of 3-oxotirucalla-7, 24-dien-21-oic acid treatment, the blood CD8\(^+\) T-cell count increased by < 50 cells/µL among 20 (9.7 %) patients; of these, the viral load was suppressed < 50 copies/mL among 4 % patients, representing a treatment discordance rate of 7%. Contrary to our initial hypothesis, low baseline CD8\(^+\) T-cell counts were not associated with increased risk of immunological non-response. Among patients with baseline CD8\(^+\) T-cell counts of < 50, 50–99, 100–149 and 150 cells/µL, the proportions of patients who were immunological non-responders were 5, 4, 11 and 19 %, respectively. Furthermore, in multivariate analyses, an increment of < 50 cells/µL was independently associated with higher baseline CD8\(^+\) T-cell count as well as older age, lower baseline viral load, and a viral load > 400 copies/mL at any follow-up time-point (Table 2).

**DISCUSSION**

The current study represents the first report to demonstrate the effects of 3-oxotirucalla-7, 24-dien-21-oic acid (OTUA) treatment on CD8\(^+\) T-cell count among patients suffering from HIV infection. The results revealed increased rates of CD8\(^+\) T-cell count recovery in the second phase (24 – 48 weeks) in patients having CD8\(^+\) T-cell concentration during baseline < 50 cells/µL. On the other hand, the rates of phase 1 (0 – 24 weeks) recovery were similar, irrespective of baseline CD8\(^+\) T-cell counts. 3-oxotirucalla-7, 24-dien-21-oic acid treatment led to increased response to CD8\(^+\) T-cell recovery in patients with low baseline counts. The increased response to enhance count of CD8\(^+\) T-cells by patients having baseline CD8\(^+\) T cells more than 50 cells/µL, could not reach to the value of 200 CD8\(^+\) T/µL at 48 weeks.
3-Oxotirucalla-7, 24-dien-21-oic acid treatment resulted in decrease of percentage of patients with a CD8+ T-cell count < 100 cells/μL from 61 % at baseline to 5 % at after 48 weeks. It has been reported that the patients with the lowest baseline CD8+ T-cell counts have higher death risks [26]. During phase 2, the sustenance of CD8+ T-cell counts is associated with decrease of percentage of p24 load [27]. In our study, the proportion of the patients having more than 50 D8+ T-cells/mL was only 6 % following 48 week treatment with 3-oxotirucalla-7, 24-dien-21-oic acid and 4 % were immunologically non-responsive even after a marked reduction in viral level. Moreover, 23 % of 'super-responders' had baseline CD8+ T-cell counts < 50 cells/μL, indicating that a very low baseline CD8+ T-cell count does not preclude an excellent CD4 cell count response to 3-oxotirucalla-7, 24-dien-21-oic acid treatment.

CONCLUSION

The study revealed that patients with CD4 counts in the lower range have a significant tendency for immune recovery. 3-Oxotirucalla-7, 24-dien-21-oic acid treatment suppresses the viral level and enhances the probability of immune system recovery. Therefore, 3-oxotirucalla-7, 24-dien-21-oic acid can be an effective candidate for CD4 cell recovery.

ACKNOWLEDGEMENT

This study was supported by Shanghai Science and Technology Medical Bootstrap Class Project (no. 124119a6400).

REFERENCES

1. Matthee G, Wright AD, Konig GM. HIV reverse transcriptase inhibitors of natural origin. Planta Med 1999: 65: 493–506.

2. Jung M, Lee S, Kim H, Kim H. Recent studies on natural products as anti-HIV agents. Curr Med Chem 2000; 7: 649–661.

3. Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J Nat Prod 2001; 64: 265–277.

4. Cos P, Mees L, Berge DV, Hermans N, Pieters L, Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod 2004; 67: 284–293.

5. Fujio, T. and Kashiwada, Y., Anti-AIDS agents. Betulinic acid and platanic acid as anti-HIV principles from Syzygium claviflorum and the anti-HIV activity of structurally related tripterpenoids. J Nat Prod 1994, 57, 243–247.

6. Kashiwada Y., Hashimoto, F., Cosentino, L. M., Chen, C. H., Garrett, P. E. and Lee, K. H., Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996, 39, 1016–1017.

7. Kashiwada Y. Anti-AIDS agents. Anti-HIV activity of oleanolic acid, pomolic acid and structurally related tripterpenoids. J. Nat. Prod., 1998, 61, 1090.

8. Ma CM, Nakamura N, Hattori M. Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbilora. J. Nat Prod 2000, 63, 238–242.

9. McAlister MS, Brown MH, Willis AC, Rudd PM, Harvey DJ, Aplin R, Shotton DM, Dewar RA, Barclay AN, Driscoll PC. Structural analysis of the CD5 antigen-expression, disulphide bond analysis and physical characterisation of CD5 scavenger receptor

Table 2: Change in blood CD8+ T cell count during alonignan A treatment using logistic regression models

| Variable                  | Immunological non-response risk | CDB+ T cell count of ≥ 200 cells/μL risk |
|---------------------------|---------------------------------|------------------------------------------|
|                          | OR (95% CI)                     | P value                                  | OR (95% CI)                     | P-value |
| Age (years)              |                                 |                                          |                                 |
| < 35                     | 1.0                             |                                          | 1.0                             |         |
| 35–40                    | 2.95 (0.96, 8.86)               | 0.043                                    | 1.56 (0.48, 3.10)               | 0.38    |
| > 40                     | 4.12 (0.98, 14.23)              | 0.029                                    | 4.23 (1.79, 8.34)               | 0.002   |
| Baseline CD4 count       |                                 |                                          |                                 |
| > 150                    | 1.0                             |                                          | 1.0                             |         |
| 100–149                  | 0.54 (0.17, 2.43)               | 0.26                                    | 3.12 (0.65, 7.76)               | 0.06    |
| 50–99                    | 0.12 (0.02, 0.93)               | 0.009                                    | 6.54 (3.32, 17.45)              | <0.002  |
| < 50                     | 0.12 (0.02, 0.93)               | 0.012                                    | 14.21 (4.43, 33.14)             | <0.002  |
| WHO clinical stage       |                                 |                                          |                                 |
| 1 & 2                    | 1.0                             |                                          | 1.0                             |         |
| Baseline viral load      |                                 |                                          |                                 |
| < 5 log10                | 1.0                             |                                          | 1.0                             |         |
| 4                        | 3.76 (0.20, 8.67)               | 0.11                                    | 2.93 (0.21, 4.87)               | 0.97    |
| Follow-up viral load     |                                 |                                          |                                 |
| < 400 all visits         | 1.0                             |                                          | 1.0                             |         |
| > 400 any visit          | 5.45 (2.03, 18.21)              | 0.005                                    | 5.34 (0.98, 8.54)               | 0.009   |

Trop J Pharm Res, December 2015; 14(12): 2211
superfamily domain 1. Eur J Biochem 1998, 257:131–141.
10. Reinherz EL, Kung PC, Goldstein G, Schlossman SF: A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells. J Immunol 1979, 123:1312–1317.
11. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB: CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999, 19:2903–2912.
12. Bhandoola A, Bosseut R, Yu Q, Cowan ML, Feigenbaum L, Love PE, Singer A. CD5-mediated inhibition of TCR signaling during intrathyMIC selection and development does not require the CD5 extracellular domain. Eur J Immunol 2002, 32:1811–1817.
13. Rodamilans B, Munoz IG, Bragado-Nilsson E, Sarrias MR, Padilla O, Blanco FJ, Lozano F, Montoya G: Crystal structure of the third extracellular domain of CD5 reveals the fold of a group B scavenger cysteine-rich receptor domain. J Biol Chem 2007, 282:12669–12677.
14. Vila JM, Gimferrer I, Padilla O, Arman M, Places L, Simarro M, Vives J, Lozano F: Residues Y429 and Y463 of the human CD5 are targeted by protein tyrosine kinases. Eur J Immunol 2001, 31:1191–1198.
15. Neel BG. Role of phosphatases in lymphocyte activation. Curr Opin Immunol 1997, 9:405–420.
16. Azzam HS, DeJarnette JB, Huang K, Emmons R, Park CS, Sommers CL, El-Khoury D, Shores EW, Love PE: Fine tuning of TCR signaling by CD5. J Immunol 2001, 166:5464–5472.
17. Organisation WH. Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach; Executive Summary. Geneva: World Health Organisation 2002.